The benefit of pancreatic cancer surveillance in carriers of germline <i>BRCA1/2</i> pathogenic variants

Laish, Ido; Schechter, Menachem; Dancour, Alain; Lieberman, Sari; Levi, Zohar; Goldberg, Yael; Kedar, Inbal; Hasnis, Erez; Half, Elizabeth; Levi, Gili Reznick; Katz, Lior; Vainer, Elez D.; Genzel, Dor; Aharoni, Maya; Chen‐Shtoyerman, Rakefet; Abu‐Freha, Naim; Raitses‐Gurevich, Maria; Golan, Talia; Bernstein‐Molho, Rinat; Ben Yehoyada, Merav; Gluck, Nathan; Rosner, Guy

doi:10.1002/cncr.35052

Cited by 3 publications

(1 citation statement)

References 53 publications

(115 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In 2023, a study was conducted on BRCA1/2 PV carriers and involved a total of 180 individuals [ 87 ]. The cohort included 57 (31.7%) BRCA1 , 121 (67.2%) BRCA2 and 2 (1.1%) individuals with PV in other genes ( APC , MSH6 and MSH2 ).…”

Section: Outcomes Of High-risk Individuals Undergoing Pancreatic Canc...mentioning

confidence: 99%

Aspects and outcomes of surveillance for individuals at high-risk of pancreatic cancer

Bogdanski,

van Hooft,

Boekestijn

et al. 2024

Familial Cancer

View full text Add to dashboard Cite

Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer-related deaths and is associated with a poor prognosis. The majority of these cancers are detected at a late stage, contributing to the bad prognosis. This underscores the need for novel, enhanced early detection strategies to improve the outcomes. While population-based screening is not recommended due to the relatively low incidence of PDAC, surveillance is recommended for individuals at high risk for PDAC due to their increased incidence of the disease. However, the outcomes of pancreatic cancer surveillance in high-risk individuals are not sorted out yet. In this review, we will address the identification of individuals at high risk for PDAC, discuss the objectives and targets of surveillance, outline how surveillance programs are organized, summarize the outcomes of high-risk individuals undergoing pancreatic cancer surveillance, and conclude with a future perspective on pancreatic cancer surveillance and novel developments.

show abstract

Section: Outcomes Of High-risk Individuals Undergoing Pancreatic Canc...mentioning

confidence: 99%

Aspects and outcomes of surveillance for individuals at high-risk of pancreatic cancer

Bogdanski,

van Hooft,

Boekestijn

et al. 2024

Familial Cancer

View full text Add to dashboard Cite

show abstract

The incidence of pancreatic cancer in women with a BRCA1 or BRCA2 mutation

Katona,

Lubinski,

Pal

et al. 2024

Cancer

View full text Add to dashboard Cite

BackgroundThe lifetime risk of pancreatic cancer in women with a germline mutation in BRCA1 and BRCA2 is not well established. In an international prospective cohort of female carriers of BRCA1 and BRCA2 mutations, the cumulative incidence of pancreatic cancer from age 40 until 80 years was estimated.MethodsA total of 8295 women with a BRCA1 or BRCA2 mutation were followed for new cases of pancreatic cancer. Subjects were followed from the date of baseline questionnaire or age 40 years (whichever came last) until a new diagnosis of pancreatic cancer, death from another cause, or date of last follow‐up.ResultsThirty‐four incident pancreatic cancer cases were identified in the cohort. The annual risk of pancreatic cancer between age 40 and 80 years was 0.04% for BRCA1 carriers and 0.09% for BRCA2 carriers. Via the Kaplan–Meier method, the cumulative incidence from age 40 to 80 years was 2.2% (95% CI, 1.1%–4.3%) for BRCA1 carriers and 2.7% (95% CI, 1.3%–5.4%) for BRCA2 carriers. Only two of the 34 cases reported a first‐degree relative with pancreatic cancer (hazard ratio, 4.75; 95% CI, 1.13–19.9; p = .03). Risk factors for pancreatic cancer included alcohol intake and a history of diabetes. The 5‐year survival rate for the 34 cases was 8.8%.ConclusionsThe lifetime risk of pancreatic cancer is approximately 2% in women with a BRCA1 mutation and 3% for women with a BRCA2 mutation. The poor survival in hereditary pancreatic cancer underscores the need for novel antitumoral strategies.

show abstract